Tekturna and the Use of Antihypertensives

Our Markets

Our Services

Specialties:

Tekturna and the use of Antihypertensives

A Survey of 100 Cardiologists and Primary Care Physicians

Deliverable: Survey with key findings.

Study Description:

Topic	Use of Antihypertensives and the Role of Tekturna
Respondent Type	Physicians
Specialties Covered	Primary Care, Internal Medicine, General Practice, Cardiology
Region	United States Only
Methodology	Online survey, self-administered via a Panel Intelligence website Duration: 20 minutes Size: 100 respondents Fielding Dates: November 29, 2007 to November 30, 2007

Objectives:

To assess the antihypertensives market and, in particular, the use of Tekturna

§ Breakdown of antihypertensive use

§ Duration of treatment

§ Additional versus alternative use of hypertensives

§ Comparison of Angiotensin II receptor antagonists (ARBs)

§ Perception and use of Tekturna

§ Issues that influence the use of Tekturna

§ Impact of generics on predicted future use of ARBs

Companies and Products Mentioned in This Report:

Company	Ticker Symbol	Product(s)
Novartis	NVS	Tekturna, Diovan
AstraZeneca	AZN	Atacand
Bristol-Myers Squibb/Sanofi Aventis	BMY/SNY	Avapro
Daiichi-Sankyo	DSKYF.PK	Benicar
Merck	MRK	Cozaar
Solvay	SOLB.BR	Teveten

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

§ Board-certified or eligible

§ In practice between 2 and 30 years

§ More than 70% of time in clinical practice

§ At least 50 uncomplicated hypertensive patients treated per month

Reports become free one year after the publication date.

about us